2nd Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Period 2nd Quarter 2019 Filed Jul 22, 2019 Signed by Dolly Judge, Vice President, U.S. Government Affairs

Official filing

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
TEVA PHARMACEUTICALS USA, INC.
Client
TEVA PHARMACEUTICALS USA INC
Income
—
Expenses
$340,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 22, 2019 $340,000 Replaced
2nd Quarter - Amendment Oct 21, 2019 $780,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S.340/HR 965-Creating & Restoring Equal Access to Equivalent Samples Act ("Creates Act"); HR 985-Fast Generics Act; S.64-Preserve Access to Affordable Generic & Biosimilars Act; HR 1499-Protecting Consumer Access to Generic Drugs Act; HR 1344-Competitive Drugs Act of 2019; HR 938-Bringing Low Cost Options & Competition While Keeping Incentives for New Generics Act ("BLOCKING Act"); HR 1506-Fair & Immediate Release of Generic Drugs Act; HR 1520-Purple Book Continuity Act; HR 1503-Orange Book Transparency Act; S.344/HR 990-Hatch-Waxman Integrity Act; Stronger Patents Act; S.1895, Lower Health Care Costs Act; and Administration review of drug pricing policies.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
DOLLY A JUDGE —
COLMAN BRENDAN RAGAN New —

Contacted: U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: H.R. 985 (116th), H.R. 1503 (116th), S. 64 (116th), H.R. 965 (116th), H.R. 1499 (116th), H.R. 990 (116th), H.R. 938 (116th), S. 1895 (116th), H.R. 1344 (116th), S. 344 (116th), H.R. 1520 (116th), S. 340 (116th), H.R. 1506 (116th)

Trade (domestic/foreign) TRD

US-Mexico-Canada Agreement (issues relating to IP Chapter)

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
DOLLY A JUDGE —
COLMAN BRENDAN RAGAN New —

Contacted: Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.